The Conundrum of Genetic “Drivers” in Benign Conditions

The Case for a Pre-Cancer Genome Atlas (PCGA)

(2016) J. D. Campbell et al.   Cancer Prevention Research

Transforming Cancer Prevention through Precision Medicine and Immune-oncology

(2016) T. W. Kensler et al.   Cancer Prevention Research

A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation

(2016) C. K. Kaufman et al.   SCIENCE

Oral Cancer Chemoprevention—The End of EPOC, the Beginning of an Epoch of Molecular Selection

(2016) Julie E. Bauman et al.   JAMA Oncology

Erlotinib and the Risk of Oral Cancer

(2016) William N. William et al.   JAMA Oncology

Molecular phenotypes of DCIS predict overall and invasive recurrence

(2015) K. E. Williams et al.   ANNALS OF ONCOLOGY

Cancer spectrum and frequency among children with Noonan, Costello and cardio-facio-cutaneous syndromes

(2015) C P Kratz et al.   BRITISH JOURNAL OF CANCER

The role ofBRAFmutations in primary melanoma growth rate and survival

(2015) V.J. Mar et al.   BRITISH JOURNAL OF DERMATOLOGY

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications

(2015) Teresa Helsten et al.   CANCER AND METASTASIS REVIEWS

HER2 expression status in diverse cancers: review of results from 37,992 patients

(2015) Min Yan et al.   CANCER AND METASTASIS REVIEWS

Colon Tumors with the Simultaneous Induction of Driver Mutations in APC, KRAS, and PIK3CA Still Progress through the Adenoma-to-carcinoma Sequence

(2015) J. N. Hadac et al.   Cancer Prevention Research

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics

(2015) A Parish et al.   CELL CYCLE

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer

(2015) Maria Schwaederle et al.   CELL CYCLE

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

(2015) Shumei Kato et al.   CELL CYCLE

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

(2015) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic characterization of head and neck squamous cell carcinomas

(2015)   NATURE

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas

(2015) Michael Krauthammer et al.   NATURE GENETICS

Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy

(2015) Michael Y Zhang et al.   NATURE GENETICS

The Genetic Evolution of Melanoma from Precursor Lesions

(2015) A. Hunter Shain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

High burden and pervasive positive selection of somatic mutations in normal human skin

(2015) I. Martincorena et al.   SCIENCE

Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA

(2015) Evgeny Izumchenko et al.   Nature Communications

CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma

(2015) A. S. McNeal et al.   Cancer Discovery

NF2/Merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations

(2015) Rebecca Dunbar Schroeder et al.   Oncotarget

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

(2015) Rabih Said et al.   Oncotarget

Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity

(2015) Adrienne L. Watson et al.   Oncotarget

Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer

(2015) Bo Tang et al.   Scientific Reports

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Molecular Profiling of Premalignant Lesions in Lung Squamous Cell Carcinomas Identifies Mechanisms Involved in Stepwise Carcinogenesis

(2014) A. T. Ooi et al.   Cancer Prevention Research

Notch1 Mutations Are Drivers of Oral Tumorigenesis

(2014) E. Izumchenko et al.   Cancer Prevention Research

Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence

(2014) Moriah H. Nissan et al.   CANCER RESEARCH

HER2 aberrations in cancer: Implications for therapy

(2014) Min Yan et al.   CANCER TREATMENT REVIEWS

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

(2014) Carlo Gambacorti Passerini et al.   JNCI-Journal of the National Cancer Institute

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Near-genomewide RNAi screening for regulators of BRAFV600E-induced senescence identifiesRASEF, a gene epigenetically silenced in melanoma

(2014) Joanna Kaplon et al.   Pigment Cell & Melanoma Research

KRAS: feeding pancreatic cancer proliferation

(2014) Kirsten L. Bryant et al.   TRENDS IN BIOCHEMICAL SCIENCES

Defining Key Signaling Nodes and Therapeutic Biomarkers in NF1-Mutant Cancers

(2014) C. F. Malone et al.   Cancer Discovery

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes

(2013) H. Henary et al.   ANNALS OF ONCOLOGY

The RASopathies

(2013) Katherine A. Rauen   Annual Review of Genomics and Human Genetics

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

NRAS Mutation Is the Sole Recurrent Somatic Mutation in Large Congenital Melanocytic Nevi

(2013) Christelle Charbel et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Melanoma prone families withCDK4germline mutation: phenotypic profile and associations withMC1Rvariants

(2013) Hanne Eknes Puntervoll et al.   JOURNAL OF MEDICAL GENETICS

BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?

(2013) M. Saroufim et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia

(2013) Iwei Yeh et al.   JNCI-Journal of the National Cancer Institute

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment

(2013) Gerald S. Falchook et al.   Journal of Thoracic Oncology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

Sturge–Weber Syndrome and Port-Wine Stains Caused by Somatic Mutation in GNAQ

(2013) Matthew D. Shirley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi

(2013) Philipp Tschandl et al.   PLoS One

Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib

(2012) Holger A. Haenssle et al.   ARCHIVES OF DERMATOLOGY

Mechanisms of FGFR-mediated carcinogenesis

(2012) Imran Ahmad et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

(2012) E Rakovitch et al.   BRITISH JOURNAL OF CANCER

Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors

(2012) M. Endo et al.   CLINICAL CANCER RESEARCH

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis

(2012) L. C. W. Vredeveld et al.   GENES & DEVELOPMENT

Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations

(2012) Karen W. Gripp et al.   GENETICS IN MEDICINE

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations

(2012) Filip Janku et al.   JOURNAL OF CLINICAL ONCOLOGY

Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing SelectiveBRAFInhibition

(2012) Lisa Zimmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA

(2012) Marjorie J Lindhurst et al.   NATURE GENETICS

De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly

(2012) Jeong Ho Lee et al.   NATURE GENETICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

MAP kinase signaling and inhibition in melanoma

(2012) R J Sullivan et al.   ONCOGENE

Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes

(2011) Christian P. Kratz et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS

Proinvasion Metastasis Drivers in Early-Stage Melanoma Are Oncogenes

(2011) Kenneth L. Scott et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model

(2011) Aurélie Jonquoy et al.   HUMAN MOLECULAR GENETICS

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Patients With Advanced Neurofibromatosis Type 2 With Novel Molecularly Targeted Therapies: From Bench to Bedside

(2011) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment

(2011) E. Grande et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma

(2011) N. J. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Circulating Benign Nevus Cells Detected by ISET Technique

(2010) Vincenzo De Giorgi et al.   ARCHIVES OF DERMATOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence

(2010) Lyndee L. Scurr et al.   CELL

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

(2010) J. Dupont Jensen et al.   CLINICAL CANCER RESEARCH

Cellular senescence: putting the paradoxes in perspective

(2010) Judith Campisi   CURRENT OPINION IN GENETICS & DEVELOPMENT

FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes

(2010) Christian Hafner et al.   EXPERIMENTAL CELL RESEARCH

Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations

(2010) Christian Hafner et al.   EXPERIMENTAL DERMATOLOGY

Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes

(2010) B. A. Virnig et al.   JNCI-Journal of the National Cancer Institute

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors

(2010) C. Hafner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development

(2010) A. M. Gustafson et al.   Science Translational Medicine

Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours

(2009) Y. Hida et al.   BRITISH JOURNAL OF DERMATOLOGY

Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy

(2009) K. S.M. Smalley et al.   CANCER RESEARCH

The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation

(2009) William E Tidyman et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Lack of Correlation between IGFBP7 Expression and BRAF Mutational Status in Melanoma

(2009) David Schrama et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Neurofibromatosis type 1

(2009) Kevin P. Boyd et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

A comprehensive catalogue of somatic mutations from a human cancer genome

(2009) Erin D. Pleasance et al.   NATURE

The cancer genome

(2009) Michael R. Stratton et al.   NATURE

Neurofibromatosis type 2 (NF2): A clinical and molecular review

(2009) D Gareth R Evans   Orphanet Journal of Rare Diseases

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7

(2008) Narendra Wajapeyee et al.   CELL

Cellular senescence in vivo: a barrier to tumorigenesis

(2008) Alexandre Prieur et al.   CURRENT OPINION IN CELL BIOLOGY

In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation

(2008) Tiziana Venesio et al.   MODERN PATHOLOGY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Many roads lead to oncogene-induced senescence

(2008) S Courtois-Cox et al.   ONCOGENE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE